Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza A (H5N1) vaccine, inactivated, split virion
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Influenza A (H5N1) vaccine, inactivated, split virion, is a pharmaceutical drug designed for active immunization against the influenza A virus H5N1 subtype. This vaccine is produced by inactivating the virus and then splitting it into components, primarily to present the viral hemagglutinin antigen to the immune system. This process stimulates the body to produce antibodies that can block the H5N1 virus from attaching to and infecting human respiratory epithelial cells, thereby preventing disease. Sanofi Pasteur is a key developer and manufacturer of this type of vaccine.
- Brand names
- AudenzArepanrixAflunovCelldemicIncellipanInfluenza Virus Vaccine, H5N1
- Other names
- H5N1 influenza vaccine - SanofiH-5N1 influenza vaccine - SanofiH 5N1 influenza vaccine - SanofiH5N1 split antigen influenza vaccine Alum adjuvanted - SanofiH-5N1 split antigen influenza vaccine Alum adjuvanted - SanofiH 5N1 split antigen influenza vaccine Alum adjuvanted - SanofiLow-dose H5N1 vaccine - SanofiPandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/Vietnam/1194/2004 (NIBRG-14) - SanofiPandemic influenza vaccine - Sanofi
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza A (H5N1) vaccine, inactivated, split virion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza A (H5N1) vaccine, inactivated, split virion.